The stock of Recro Pharma, Inc. (NASDAQ:REPH) is now priced at $4.46 and the shares are -0.14 points down or -3.04% lower compared to its previous closing price of $4.6. The stock had 412886 contracts set over the past session. REPH shares’ daily volume is compared to its average trading volume at 582303 shares. However, it has a float of 23.19 million and although its performance was -3.04% over the week, it’s one to watch. REPH share price recently placing at $4.44 to $4.74. However, some brokerage firms have priced the stock below the average, including one that has called $9.
The shorts are climbing into the Recro Pharma, Inc. stock, with the latest data on short interest released on June 15, 2020, showing that short interest numbers in the REPH shares have risen. Short interest in the stock represents just 4.06% of its float, but the volume has raised by 72913. The volume of shorted shares rised to 940918 from 868005 shares over the last two weeks. The average intraday trading volume has been 574362 shares, which means that days to cover moved to roughly 1.638197.
In the last trading session, Recro Pharma, Inc. (NASDAQ:REPH) dropped by -$0.14 over the week and lost -$0.49 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $19.21. The stock recorded its established 52-week high on 02/13/20.
Since 05/14/20, the stock has traded to a low of $4.15 at 7.47%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0.81. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Recro Pharma, Inc.’s two-week RSI is 32.78. This suggests that the stock is neutral at the moment and that REPH shares’ price movement remains stable. The stochastic readings are equally revealing at 8.21% meaning the REPH share price is currently in overbought territory.
The technical chart shows that the REPH stock will likely settle at between $4.65 and $4.85 per share. However, if the stock dips below $4.35, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $4.25.
Currently, the stock is trading in the red of MACD, with a reading of -0.07. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned REPH a rating of Overweight in their intiating review released on October 17. Janney analysts see the stock as a Buy with a target price of $13 in a flash note released to investors on January 31 resuming covering the stock. Oppenheimer analysts see the stock as Outperform when the analysts initiated the share price coverage on February 14, placing it at $19.
The average rating for the REPH equity is 1.25 and is currently gathering a bullish momentum. Of 2 analysts tracking Recro Pharma, Inc. polled by Reuters, 0 rated REPH as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Elsewhere, the REPH stock price is 10.49X ahead of its 12-month Consensus earnings per share estimates.
Zacks Consensus Estimate forecasts that the current-quarter revenues for Recro Pharma, Inc. (NASDAQ:REPH) will decrease by about -99.91%, which will see them reach $18.88 million. The company’s full-year revenues are, however, expected to diminish by about -18.25%, down from $99.22 million to $81.11 million. REPH’s expected adjusted earnings should surge almost 23.08% to end up at -$0.16 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -361.9% to record -$0.55/share.